MX2021009055A - Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. - Google Patents
Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.Info
- Publication number
- MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating pulmonary
- ethyl
- rodatristat
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical group CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 title abstract 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798827P | 2019-01-30 | 2019-01-30 | |
| PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009055A true MX2021009055A (es) | 2021-10-22 |
Family
ID=70285725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009055A MX2021009055A (es) | 2019-01-30 | 2020-01-30 | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11607413B2 (enExample) |
| EP (1) | EP3917531A1 (enExample) |
| JP (1) | JP2022518944A (enExample) |
| KR (1) | KR20210133953A (enExample) |
| CN (1) | CN113557022A (enExample) |
| AU (1) | AU2020213746A1 (enExample) |
| CA (1) | CA3128327A1 (enExample) |
| MX (1) | MX2021009055A (enExample) |
| WO (1) | WO2020157577A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
| US11413287B2 (en) * | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020128614A1 (en) * | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| MX2021009055A (es) | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) * | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875622B2 (en) | 2007-07-11 | 2011-01-25 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2020128614A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| MX2021009055A (es) | 2019-01-30 | 2021-10-22 | Altavant Sciences Gmbh | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
| AU2020244278A1 (en) * | 2019-03-15 | 2021-09-30 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/es unknown
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/ko not_active Abandoned
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en not_active Abandoned
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/zh active Pending
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/ja active Pending
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en not_active Ceased
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210133953A (ko) | 2021-11-08 |
| CN113557022A (zh) | 2021-10-26 |
| US11607413B2 (en) | 2023-03-21 |
| US20200237759A1 (en) | 2020-07-30 |
| CA3128327A1 (en) | 2020-08-06 |
| EP3917531A1 (en) | 2021-12-08 |
| JP2022518944A (ja) | 2022-03-17 |
| WO2020157577A8 (en) | 2020-10-15 |
| AU2020213746A1 (en) | 2021-08-19 |
| US20240041877A1 (en) | 2024-02-08 |
| WO2020157577A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009055A (es) | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. | |
| US5804596A (en) | Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders | |
| US8278300B2 (en) | Use for PDE5 inhibitors | |
| EA029407B1 (ru) | Композиции и способы уменьшения содержания алкоголя в крови | |
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| US9937195B2 (en) | Edible energy composition | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| WO2014043025A1 (en) | Multiple folate formulation and use thereof | |
| JP2022518944A5 (enExample) | ||
| US20250319041A1 (en) | Compositions comprising Quinone and/or Quinol and methods of preparations and use thereof | |
| CA3119909A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| DE69826561T2 (de) | Aldose Reductase Hemmung zur Vorbeugung oder zur Umkehrung der diabetischen Kardiomyopathie | |
| US12194042B2 (en) | Uses | |
| WO1993010787A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone | |
| Singh et al. | Alcohol drinking in rats is attenuated by the mixed 5-HT1 agonist/5-HT2 antagonist FG 5893 | |
| US5217974A (en) | Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity | |
| JP4604515B2 (ja) | 眼科用剤 | |
| CN1705476A (zh) | 酒精代谢的增强 | |
| CN110101849B (zh) | 一种酶催化解酒作用的组合物及其制备方法与应用 | |
| US20210121469A1 (en) | Edible Energy Composition | |
| KR101841553B1 (ko) | 오르니친 또는 오르니친 염을 포함하는 성기능 개선용 조성물 | |
| YANG et al. | Comparative studie on nitrogen budget and energy budget of jian carp (Cyprinus carpio var. jian) and gibel carp (Carassius auratus gibelio) fed diets with different qualities | |
| EP0505640B2 (en) | Improved therapeutic method | |
| EP3927187A1 (en) | Food supplement to improve the heart function | |
| US20210077517A1 (en) | Edible Energy Composition |